STING pathway

  • Detects all respiratory infectious threats to trigger protective immune response
  • Disease occurs when pathogens compromise detection by STING
  • Restoring STING pathway offers broad-spectrum defense to multiple pathogens with one IN product, NanoSTING-001
  • Enhancing STING pathway augments all vaccines with one IN product, NanoSTING-002

IN NanoSTING-001 reduces risk of serious lower respiratory infection

  • Detects all respiratory infectious threats to trigger protective immune response
  • Disease occurs when pathogens compromise detection by STING
  • Restoring STING pathway offers broad-spectrum defense to multiple pathogens with one IN product, NanoSTING-001
  • Enhancing STING pathway augments all vaccines with one IN product, NanoSTING-002

IN NanoSTING-002 enhances mucosal immunity while delivering systemic immunity

IN vaccines trigger systemic immune responses and induce
mucosal antibodies, tissue-resident memory T-cells, and trained
immunity in the airways, forming an immune barrier against viral
invasion and providing comprehensive systemic protection.

  • Novel mucosal adjuvant shown to boost
    IN vaccine protection
  • Compatible with with multiple vaccines
  • Optimized liposomal nanoparticles for rapid
  • uptake across respiratory epithelial
  • No local or systemic toxicity – safe adjuvant
  • Convenient dosing
  • Decreases viral shedding which may block person-to-person transmission

Highlights from our Treatment & Prevention Preclinical Studies

NanoSTING platform

  • Mechanism: Activates immune response as
    therapeutic and adjuvant
  • Safety: Reassuring from multiple animal models
    (single 🡪 multiple doses)

NanoSTING-001 (IN-DHT)

  • Effective: Different pathogens and variants

  • Leap-frog: Overcomes viral resistance (superior
    to oseltamivir)

  • Transmission: Interrupts viral spread

NanoSTING-002 (IN adjuvant)

  • Effective: Enhances vaccines to stop viral
    replication in the airway and launch boost
    immune protection

Highlights from our Treatment & Prevention Preclinical Studies

SARS-CoV-2 detected on the aircraft carrier USS
Theodore Roosevelt in March 2020 while she was at
sea. On 1 April, the Navy ordered the aircraft carrier
largely evacuated. On 13 April, death of a 41-year-old
chief petty officer. On 21 May Theodore Roosevelt
entered the Philippine Sea for carrier qualification
flights with 3,000 sailors, leaving 1,800 in quarantine
on Guam.

NanoSTING-001 is being developed to provide early
response to respiratory viral infections. As a
treatment and pre-exposure prevention a convenient
self-administration of the STING agonist could reduce
the confirmed cases, speed recovery and minimize
operational impact.

Case Studies highlighting Unmet Medical Need: Immunocompromised Cancer Patients

  • Respiratory viral infections in patients with
    cancer increases morbidity and mortality and
    delays treatment
  • Concern for transmission of respiratory virus
    leads to social isolation and anxiety among
    patients with cancer
  • Infections with a heterogeneous group of respiratory viruses
  • Infections in populations with cancer are characterized by a high rate of progression from upper to lower respiratory tract infection and prolonged viral shedding
  • A critical determinant of whether a host succumbs to or can subvert a viral infection is the efficiency at which the host’s innate immunity is activated

Case Studies: Boosting the bodies immune response to Intranasal Vaccines

  • Intranasal vaccines offer major advantages to protect against
    respiratory infections, especially those with many sub-strains
    or mutant escapes such as SARS-Cov_2 or Influenza;
    however, their development to date has been hindered due to
    poor immune response.

  • NanoSTING-002 may help boost their performance and maintain their effectiveness over time by better stimulating the body’s natural first line defense and stimulating mucosal defenses in the upper and lower airway.

  • Intranasal vaccination may be especially helpful for
    Immunocompromised and patients over the age of 65
    generally experience lower vaccine protection due to impaired
    immune responses.